All In Biotech

Drug Trial Radar · NCT00952705

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age

A Randomized, Partially Blind Active Controlled Study to Evaluate the Immunogenicity of MEDI8662 in Adults 18 to 49 Years of Age

Last checked: Nov 20, 2026Latest source record: May 3, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,800

Actual

Start

Aug 2009

Primary completion

Jan 2010

Study completion Mar 2010

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 6, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study was to show that quadrivalent live attenuated influenza vaccine (Q/LAIV-BFS; MEDI8662) was at least as immunogenic as two different forms of the commercial vaccine, FluMist, by comparing the strain-specific antibody levels in the blood.

Conditions

  • Healthy or Stable Underlying Chronic Medical Condition

Interventions

  • Q/LAIV-BFS (MEDI8662)Biological

    A single dose of Q/LAIV-BFS delivered using the BFS delivery system (0.2 mL) on Day 0.

  • FluMist/B/YamagataBiological

    FluMist/B/Yamagata - 0.2 mL dose at Day 0

  • FluMist/B/VictoriaBiological

    FluMist/B/Victoria - 0.2 mL dose at Day 0

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Post Dose Strain-specific Serum Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMTs) in the Q/LAIV-BFS (MEDI8662) Arm as Compared to Those in the Combined Flumist Arms (All Flumist Group).Time frame: Day 28 to 35

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Coastal Clinical Research, Inc.

    Mobile, Alabama

  • Benchmark Research

    Sacramento, California

  • California Research Foundation

    San Diego, California

  • Benchmark Research

    San Francisco, California

  • Tampa Bay Medical Research, Inc.

    Clearwater, Florida

  • Avail Clinical Research, LLC

    DeLand, Florida

  • Miami Research Associates

    Miami, Florida

  • Clinical Research Atlanta

    Stockbridge, Georgia

  • Johnson County Clin-Trials

    Lenexa, Kansas

  • Vince and Associates Clinical Research

    Overland Park, Kansas

  • Benchmark Research

    Metairie, Louisiana

  • Sundance Clinical Research

    St Louis, Missouri

  • Meridian Clinical Research, LLC

    Omaha, Nebraska

  • Regional Clinical Research

    Endwell, New York

  • Rochester Clinical Research Inc.

    Rochester, New York

  • Palmetto Medical Research

    Mt. Pleasant, South Carolina

  • Benchmark Research Austin

    Austin, Texas

  • Benchmark Research Ft. Worth

    Fort Worth, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.